Jashin J Wu

Jashin J Wu

M.D.

About

506
Publications
36,318
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
8,761
Citations
Citations since 2016
342 Research Items
7164 Citations
201620172018201920202021202205001,0001,500
201620172018201920202021202205001,0001,500
201620172018201920202021202205001,0001,500
201620172018201920202021202205001,0001,500
Introduction

Publications

Publications (506)
Article
Importance Identifying the optimal long-term biologic therapy for patients with psoriasis is often done through trial and error. Objective To identify the optimal biologic therapy for individual patients with psoriasis using predictive statistical and machine learning models. Design, Setting, and Participants This population-based cohort study us...
Article
Phototherapy is a standard treatment for moderate-to-severe psoriasis. However, concern remains regarding the associated cutaneous carcinogenic risk. Our objective is to conduct a systematic review of skin cancer risk for psoriasis patients treated with phototherapy. To achieve our goal, we searched Cochrane, PubMed, and Embase databases. We aimed...
Article
Objective: Although biologics are highly effective in the treatment of psoriasis, some patients consistently fail monotherapy. For these patients, combination therapy is commonly employed. However, evidence-based recommendations for combination therapy in the treatment of psoriasis with interleukin-17 (IL-17) inhibitors are currently lacking. Ther...
Article
Background: Prolonged systemic antibiotic treatment is often a part of management of hidradenitis suppurativa (HS). While biologic therapies are now available, the patient's treatment journey leading to biologic therapy is unclear. Objectives: To examine treatment patterns and duration of systemic treatment use in HS patients preceding biologic...
Chapter
Since the advent of biologic treatments for psoriasis in the early 2000s, this class of medicines has proven to be a safe and effective therapeutic option in the treatment of moderate-to-severe psoriasis. Numerous biologic treatment options have been developed in the past 20 years, allowing for tailored treatment regimens for psoriasis in special p...
Article
Importance Biologics are important in treating patients with hidradenitis suppurativa (HS). However, to our knowledge, data on their real-life performance and treatment patterns in HS are limited. Objective To examine the drug survival of biologic therapies for HS in a real-world setting. Design, Setting, participants This cohort study included a...
Article
Amid the current COVID-19 pandemic, there is concern for increased risk of infection while on immunomodulatory therapy. Omalizumab, a monoclonal antibody, is an add-on therapy for the treatment of chronic idiopathic urticaria (CIU) when first line therapy alone fails to achieve appropriate response. Current understanding of the response to COVID-19...
Article
Full-text available
IntroductionAtopic dermatitis (AD) can have a profound negative impact on the quality of life (QoL) of patients. We analyzed the long-term changes in AD symptoms, QoL, and patient assessment of treatment effect in adults with moderate-to-severe AD treated for 2 years with dupilumab. MethodsLIBERTY AD OLE (NCT01949311) is a multicenter, open-label e...
Article
Full-text available
Background Risankizumab has demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis in randomized clinical trials. Objectives We evaluated safety data from risankizumab psoriasis phase 1–3 clinical trials. Methods Short-term safety (through week 16) was analyzed using integrated data from five phase 2 and 3 clinical...
Article
Background: Due to the public health risk associated with SARS-CoV-2 (COVID-19) infection, universal use of face masks has been recommended to protect against viral spread. Adverse facial reactions from the utilization of masks in the general public are poorly characterized in literature. Objective: We aimed to provide a systematic review of stu...
Article
Full-text available
IntroductionAtopic dermatitis (AD) is a systemic inflammatory condition that may increase the risk of cardiovascular disease (CVD); however, ongoing debate exists surrounding its direct association. We aimed to elucidate whether AD contributes to a higher incidence of CVD and major adverse cardiovascular events (MACE) in adult patients with AD, ind...
Article
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in patients who are eligible for phototherapy or systemic therapy. The drug increases cyclic...
Article
In April 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines regarding the management of psoriasis with a focus on its extracutaneous manifestations-comorbidities, mental health, psychosocial wellness, and quality of life (QOL). These guidelines provide the most up-to-date evidenc...
Article
Biologics have impacted the clinical management of moderate to severe psoriasis. This review article highlights new data findings from phase 3 clinical trials (N=8) published between May 2020 and February 2021. Data on the efficacy of US Food and Drug Administration-approved biologics for treating psoriasis affirms durable skin clearance in the pre...
Article
Full-text available
Purpose The aim of this review is to compare and contrast evidence‐based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis. Materials and methods Clinical practice guidelines from the American Academy of Dermatology (AAD), National Psoriasis Foundation (NPF), British Association of Dermat...
Article
Background: Interleukin (IL)-17 inhibitors are a newer class of biologic used to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: We compared evidence-based clinical practice guidelines (CPGs) from leading dermatological organizations for the use of IL-17 inhibitors in psoriasis. Methods: Guidelines f...
Article
In the context of the current coronavirus disease 2019 (COVID‐19) pandemic, there is no direct evidence to support any preferred biologic therapy for psoriasis. However, known safety profile of different classes of biologic therapies as well as individual risk factors for infections must be considered. Here, we report incidence rates of respiratory...
Article
The emergence of data from clinical trials of biologics, the approval of new biologics, and our improved understanding of psoriasis pathogenesis have increased the therapeutic possibilities for the treatment of moderate-to-severe psoriasis. Biologics currently approved for the treatment of psoriasis include tumor necrosis factor inhibitors, interle...
Poster
Full-text available
Background: In the double-blind, placebo-controlled LIBERTY AD PEDS phase 3 trial (NCT03345914) in children with severe atopic dermatitis (AD), dupilumab significantly improved AD signs and symptoms. We assess time to onset of improvement in pruritus in children treated with dupilumab. Methods: Children aged 6–11 years were randomized to dupilumab...
Article
While interleukin‐17 (IL‐17) inhibitors are effective for many patients with psoriasis, there is limited real‐world data characterizing patients who respond or do not respond to this biologic class.1 Identification of patient characteristics associated with response to this class of medication would present a significant advantage for both patients...
Article
Full-text available
Purpose of Review Deucravacitinib is an oral, selective TYK2 inhibitor that is currently in phase III of development for the treatment of psoriasis. This article reviews the mechanism and significance of TYK2 inhibition, as well as the current data on the safety and efficacy of deucravacitinib. Recent Findings Phase II results for deucravacitinib...
Article
Free open access data sources are a valuable tool for dermatology researchers and may uncover crucial information about dermatological diseases and delivery of dermatological care. This short review discusses six open access data sources including: National Health and Nutrition Examination Survey (NHANES), National Health Interview Survey (NHIS), N...
Article
Full-text available
Introduction: A number of treatments for atopic dermatitis (AD) are available; however, long-term treatment patterns and healthcare consumption in patients with AD are poorly described. Methods: We conducted a registry-based longitudinal drug utilization study among Danish patients with AD that were referred to their first-ever visit at hospital...
Article
To the Editor: Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease associated with arthritis of inflammatory etiology such as rheumatoid arthritis¹. To date, the association between AD and non‐inflammatory arthritides remains unknown. This study sought to determine whether AD is associated with increased risk of osteoarthritis (...
Article
In 2020, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines for the management of psoriasis in adults with systemic nonbiologic therapies, including acitretin, apremilast, cyclosporine, fumaric acid esters, methotrexate, and tofacitinib. This review addresses dosing, efficacy, toxicity...
Chapter
IL-23 inhibitors are a newer class of biologics that specifically target the p19 subunit of IL-23, a cytokine believed to play an important role in the pathogenesis of psoriasis. Currently, three IL-23 inhibitors have been developed for psoriasis: guselkumab, tildrakizumab, and risankizumab. Guselkumab was US Food and Drug Administration (FDA) appr...
Chapter
Risankizumab is a humanized IgG1 monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23). It has demonstrated substantial clinical efficacy in the treatment of psoriasis. This chapter reviews the efficacy and safety of risankizumab for the treatment of psoriasis as evidenced by the clinical trials to date. Four phase III trials h...
Article
Full-text available
Introduction: Psoriasis, an immune-mediated disease that manifests cutaneously with possible arthritic complications, affects millions of people in the United States and worldwide. Depression and suicidal ideation and behavior (SIB) are two prevalent comorbidities associated with psoriasis, due to the chronic nature of the disease, lack of a cure,...
Article
The occurrence of the COVID-19 pandemic has raised new uncertainties for dermatologists and their patients, importantly concerning initiation and continuation of immunosuppressants for dermatological conditions at this time. We review two phase III trials of rituximab, a chimeric CD20 monoclonal antibody, used for the treatment of pemphigus vulgari...
Article
Background: Real-world data on patients newly initiating ixekizumab is limited. Our study describes the characteristics of patients who initiated ixekizumab and other biologics for psoriasis treatment in North American dermatological practices. Materials & methods: Characteristics of patients ascertained at registry enrollment are described via mea...
Article
Full-text available
Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the United States, brodalumab carries a boxed warning about suicidal...
Article
Full-text available
Brodalumab, a first-in-class interleukin-17 (IL-17) receptor blocker, carries a black box warning for suicidal ideation and behavior, yet it is also one of the most powerful biologic agents in our armamentarium. We wish to highlight three patients with moderate-to-severe psoriasis and comorbid depression who were successfully treated with brodaluma...
Article
In November 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released their recommendations regarding management of psoriasis in pediatric patients. The guidelines include information on quantification of disease severity, identification of triggers, assessment of comorbidities, and therapeutics specific t...
Article
Full-text available
Background: The influence of comorbidities on the efficacy and safety of biologic therapies in psoriasis has not been rigorously explored. Objective: To assess the incremental burden of comorbidities on clinical efficacy and safety of secukinumab vs. etanercept and placebo among patients with plaque psoriasis pooled from 4 phase 3 trials. Metho...
Article
Mild to moderate atopic dermatitis (AD) occurs frequently in children and adults and is usually managed through the use of pharmacologic treatments, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), and good skin care practices. As chronic TCS or TCI can lead to the development of adverse effects, there is a need for...
Article
Psoriasis is an inflammatory disease with both skin and joint manifestations. Focused biologics have been developed to target specific cytokines implicated in psoriasis and are becoming increasingly utilized. Recently, the advent of newer biologics, including IL-17, IL-12/IL-23, and IL-23 inhibitors, have garnered interest as promising treatments f...
Article
Purpose: This review article aims to compare global dermatologic organizations and the clinical practice guidelines available for the use of interleukin (IL)-23 inhibitors in the treatment of psoriasis. Materials and methods: A literature review encompassing systemic therapies for the treatment of psoriasis was conducted. Guidelines from the Ame...
Article
Full-text available
With the increasing availability of biosimilars, the practice of switching therapies for non-medical reasons between an originator biologic and an analogous biosimilar has become more common. The evidence to support this practice mostly comes from single-switch randomized controlled trials (RCTs) and real-world (RW) evidence studies. However, as mo...
Article
Background: There is an increasing number of over-the-counter topical products that are said to prevent pathologic scar formation and improve scar cosmesis. However, robust clinical data are lacking to substantiate these claims and to guide selection of topical products. Objective: To determine the effectiveness of topical scar management produc...
Article
A concern with the increasing use of prescription drugs during pregnancy is teratogenic risk. This risk is undetermined for most drugs approved in the United States (US) from 2000 to 2010. Acne and psoriasis are chronic diseases that typically occur during the child-bearing years, and as topical retinoids are recommended for both acne and psoriasis...